~~<i id='3E8885116A'><strike id='3E8885116A'><tt id='3E8885116A'><pre id='3E8885116A'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：Wikipedia 2025-09-06 07:21:07 Page View：4432

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Judge schedules Friday hearing on proposed protective order in Jan. 6 case
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

leisure time

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

1:37FacebookCEOMarkZuckerbergspeaksabout"NewsTab"atthePaleyCenter,Oct.25,2019,inNewYork.MarkLennihan

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

2:18CarlosDeOliveira(L),propertymanagerofformerUSPresidentDonaldTrump'sMar-a-LagoestateinPalmBeach,a